Company intelligence / Profile preview

ExactCure

Nice, Francequery.prod.cms.rt.microsoft.com ↗

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

ExactCure developed a CE-marked digital health solution that simulates the concentration of drugs in a patient's blood based on individual characteristics. The tool aims to reduce medication errors and optimize dosing. As of May 2021, it was certified as a class I medical device in Europe and was being upgraded to class IIa status. In April 2024, the company merged with Quantum Genomics to accelerate development and deployment.

No clinical trial results are reported as this is a software/device company.

Therapeutic areas: Other
Modalities: Non-pharmacological therapy (software-based simulation platform)
Industry: Digital Health Medical Devices

Partnerships

Vidal (French leader in medical information)Elsevier (global medical publishing)UPSA (pharma partner for mobile app launch)

Beyond the preview

Go deeper on ExactCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExactCure.

Explore the full profile